Not exact matches
A combination of fostamatinib and paclitaxel reduced
tumor size in six mice by up to 87 percent,
compared with no shrinkage in six untreated animals after three weeks.
After five weeks, the combination treatment in the six mice decreased
tumor size by up to 66 percent,
compared with six mice treated with only paclitaxel.
The study measured overall reduction in
tumor size and then
compared this reduction to the time until a controlled
tumor started to grow (PFS) and patient overall survival (OS).
«Our study aimed to
compare contrast - enhanced mammography with breast MRI in evaluating residual breast cancer in patients undergoing presurgical systemic treatment to shrink their
tumor size,» says Bhavika Patel, M.D., a radiologist at Mayo Clinic's Arizona campus.
The importance of stromal POSTN was also demonstrated in another study in which orthotopic inoculation of gastric cancer cells into Rag2 − / −; Postn − / − mice reduced
tumor size, decreased invasiveness, and decreased growth
compared to Rag2 − / −; Postn + / + mice (Kikuchi et al., 2014).
It's easy to imagine that a drug for cancer can be tested by measuring the
size of
tumors in patients who take the drug,
compared with those that don't.
A, HIF - 1α and Glut1 expression in ER - α — positive (i) and negative (ii) xenografts
compared with
tumor size (mm3).
At five months, when
tumors had already began to form, there was little inhibitory effect observed when
comparing tumor numbers or
sizes to control groups.
These breast cancer mice were then treated with Bioidentical Hormones (estradiol, progesterone, testosterone) showing a dramatic reduction in
tumor size, with better results
compared to conventional aromatase treatment.
Decreases in
tumor size that lasted for a minimum of six months were seen in about 16 percent of patients who received Imlygic,
compared with about 2 percent of those who received the other treatment, the findings showed.